Zobrazeno 1 - 10
of 51
pro vyhledávání: '"J. Enejosa"'
Autor:
Patrick Durez, Tim Shaw, In-Ho Song, Yihan Li, Xenofon Baraliakos, Charles Peterfy, Alan Friedman, Eduardo Mysler, Su Chen, Mark C. Genovese, Vibeke Strand, J. Enejosa, Stephen Hall
Publikováno v:
Rheumatology. 59
Background Long-term prevention of structural joint damage is a key treatment goal in the management of RA. Upadacitinib (UPA), a JAK1-selective inhibitor, inhibited the progression of structural joint damage at 6 months as monotherapy in methotrexat
Autor:
Kevin L. Winthrop, J. Ignacio Vargas, Alan Friedman, Alan Kivitz, J. Enejosa, N. Khan, C. Garcia Garcia, E. Drescher, J. Klaff, Y. Li
Publikováno v:
Annals of the Rheumatic Diseases. 80:486.3-487
Background:Pneumococcal vaccination is recommended in patients with RA who are receiving conventional synthetic/biologic DMARDs.1 Upadacitinib (UPA) is an oral Janus kinase (JAK) inhibitor engineered to have a greater selectivity for JAK1 versus JAK2
Autor:
Stanley Cohen, T. Shaw, Yoshiya Tanaka, C. Schlacher, Louis Bessette, R. van Vollenhoven, Yeong Wook Song, J. Liu, Jeffrey R. Curtis, G.-R. Burmester, J. Enejosa, L. Calabrese, C. Zerbini
Publikováno v:
Annals of the Rheumatic Diseases. 79:319-320
Background:The safety and efficacy of upadacitinib (UPA), an oral JAK inhibitor, was evaluated in the phase 3 SELECT clinical program, which included 5 randomized, double-blind, controlled trials across a spectrum of rheumatoid arthritis (RA) patient
Autor:
Stephen Hall, Charles Peterfy, Xenofon Baraliakos, Mark C. Genovese, Tim Shaw, Eduardo Mysler, I. H. Song, Alan Friedman, Vibeke Strand, Y. Li, J. Enejosa, Patrick Durez, Y. Song
Publikováno v:
Annals of the Rheumatic Diseases. 79:330-331
Background:For patients with rheumatoid arthritis (RA), long-term prevention of structural joint damage is a key treatment goal.1In the SELECT-EARLY and SELECT-COMPARE trials, upadacitinib (UPA), an oral JAK inhibitor, inhibited the progression of st
Autor:
Y. Zhang, Aileen L. Pangan, Boulos Haraoui, N. Martin, Maureen Rischmueller, Ricardo Machado Xavier, J. Enejosa, A. Rubbert-Roth, Mark C. Genovese, N. Khan
Publikováno v:
Annals of the Rheumatic Diseases. 79:1015-1016
Background:Upadacitinib (UPA) is an oral, reversible, selective JAK 1 inhibitor approved for the treatment of moderate to severe rheumatoid arthritis (RA). The efficacy/safety of UPA has been demonstrated in phase 3 studies, including superiority to
Autor:
Kevin L. Winthrop, Kunihiro Yamaoka, J. Suboticki, Eduardo Mysler, N. Khan, P. Nash, J. Enejosa, Y. Song, L. Calabrese, Jeffrey R. Curtis
Publikováno v:
Annals of the Rheumatic Diseases. 79:335-336
Background:Upadacitinib (UPA) is an oral JAK inhibitor approved for the treatment of rheumatoid arthritis (RA). The background rate of herpes zoster (HZ) in patients (pts) with RA is around 0.98/100 person years (PY)1. Pts with RA receiving JAK inhib
Autor:
K. Cherny, Barbara Hendrickson, A. Ostor, S. Jeka, A. Broadwell, K. Dunlap, J. Suboticki, Sheng Zhong, Grace C. Wright, Michael E. Weinblatt, J. Enejosa, Eduardo Mysler
Publikováno v:
Annals of the Rheumatic Diseases. 79:653-654
Background:Upadacitinib (UPA), an oral selective JAK1 inhibitor, has demonstrated favorable efficacy and acceptable safety in five Phase 3 global studies in patients with moderately to severely active rheumatoid arthritis (RA).1–5Objectives:This an
Autor:
Roy Fleischmann, Yan Song, Vibeke Strand, Namita Tundia, Casey Schlacher, In-Ho Song, J. Enejosa, Martin J. Bergman, A. Ostor, Patrick Durez
Publikováno v:
Poster Presentations.
Background Upadacitinib (UPA), a selective JAK1 inhibitor, has demonstrated superior improvement in the clinical signs and symptoms of rheumatoid arthritis (RA) compared with placebo (PBO) and adalimumab (ADA).1 Objectives To evaluate the effect of U
Autor:
Roy Fleischmann, Glen T. D. Thomson, LI Yihan, Ricardo Blanco, Ryan DeMasi, J. Enejosa, Cristiano A. F. Zerbini, Stephen Hall, In-Ho Song, Mark C. Genovese, Filip Van den Bosch
Publikováno v:
Oral Presentations.
Background Initiating advanced therapy for rheumatoid arthritis (RA) patients (pts) with a bDMARD or a Janus kinase (JAK) inhibitor is recommended if remission or low disease activity (LDA) is not achieved with csDMARDs.1,2 While data show that pts a
Autor:
Patrick Durez, LI Yihan, Stephen Hall, Su Chen, Eduardo Mysler, Alan Friedman, J. Enejosa, Mark C. Genovese, Charles Peterfy, Xenofon Baraliakos, In-Ho Song, Tim Shaw, Vibeke Strand
Publikováno v:
Poster Presentations.
Background Long–term prevention of structural joint damage is a key treatment goal in the management of RA1. Upadacitinib (UPA), a JAK1-selective inhibitor, inhibited the progression of structural joint damage at 6 months as monotherapy in methotre